ABPO (Abpro Holdings) ROE %: 0.00% (As of Mar. 2026)


ABPO Abpro Holdings Inc ABPO
9 GF Score
Price $0.22
! 1 Warning Sign
View Full Analysis

What is Abpro Holdings ROE %?

Abpro Holdings ABPO +3.66% 9 ROE % is 0.00% as of Mar. 2026. GuruFocus rates ABPO with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 1,255 Biotechnology companies, Abpro Holdings ranks worse than 79681.2% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Abpro Holdings's annualized net income for the quarter that ended in Mar. 2026 was $-4.11 Mil. Abpro Holdings's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $-5.82 Mil. Therefore, Abpro Holdings's annualized ROE % for the quarter that ended in Mar. 2026 was N/A%.

The historical rank and industry rank for Abpro Holdings's ROE % or its related term are showing as below:

ABPO's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.18
* Ranked among companies with meaningful ROE % only.

Abpro Holdings  (OTCPK:ABPO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-4.112/-5.816
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.112 / 0)*(0 / 3.964)*(3.964 / -5.816)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-4.112/-5.816
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-4.112 / -4.112) * (-4.112 / -3.732) * (-3.732 / 0) * (0 / 3.964) * (3.964 / -5.816)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.1018 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Abpro Holdings ROE % Related Terms


Abpro Holdings ROE % Historical Data

* Premium members only.

The historical data trend for Abpro Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abpro Holdings ROE % Chart

Abpro Holdings Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE %
0.00 0.00 0.00 0.00

Abpro Holdings Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 Negative Equity 0.00

ABPO vs LYRA, ATXI, PTIX: ROE % Comparison

For the Biotechnology subindustry, Abpro Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abpro Holdings ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abpro Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Abpro Holdings's ROE % falls into.


ABPO
9GF Score
Abpro Holdings Inc ABPO
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abpro Holdings ROE % Calculation

Abpro Holdings's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-2.892/( (-15.495+-8.831)/ 2 )
=-2.892/-12.163
=N/A %

Abpro Holdings's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-4.112/( (-8.831+-2.801)/ 2 )
=-4.112/-5.816
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Abpro Holdings (ABPO) has a ROE % of 0.00% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Abpro Holdings and its competitors. According to the industry distribution chart, Abpro Holdings ranks #999999 out of 1255 companies in the Biotechnology industry.
Is Abpro Holdings' ROE % too high?
Abpro Holdings' current ROE % is 0.00%. Based on the distribution chart, Abpro Holdings ranks #999999 out of 1255 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abpro Holdings has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Abpro Holdings' ROE % compare to LYRA and ATXI?
According to the Biotechnology industry distribution chart, Abpro Holdings ranks #999999 out of 1255 companies for ROE %. This places Abpro Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Abpro Holdings and its competitors. Abpro Holdings's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abpro Holdings stock overvalued right now?
Abpro Holdings (ABPO) has a current ROE % of 0.00%. The current ROE % is 0.00%. Abpro Holdings' overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Abpro Holdings (ABPO), the current ROE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abpro Holdings Business Description

Address 100 Summit Drive, Burlington, MA, USA, 01803
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. The company is focused on novel antibody constructs for immuno-oncology, ophthalmology, and infectious diseases. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, the company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
9GF Score

Get the complete analysis for ABPO

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.22
Price